Long-term ECG monitoring. Significance for primary and secondary prevention of thromboembolic events in atrial fibrillation
https://doi.org/10.17802/2306-1278-2018-7-4S-94-100
Abstract
The review presents current data on the use of the long-term ECG monitoring for the management of patients with atrial fibrillation (AF). Long-term ECG monitoring allows receiving large amounts of diagnostic data and optimizes clinical management by the timely start of anticoagulant therapy in the patients with silent AF. This is a crucial issue for prevention of thromboembolic events.
About the Authors
T. Y. Chichkova
Federal State Budgetary Institution Research Institute for Complex Issues of Cardiovascular Diseases
Russian Federation
Competing Interests: Нет конфликта интересов
Russian Federation
Chichkova Tatyana Yu. - researcher at the Laboratory of Cardiac Arrhythmia and Pacing.
6, Sosnoviy Blvd., Kemerovo, 650002
Competing Interests: Нет конфликта интересов
I. E. Mamchur
Federal State Budgetary Institution Research Institute for Complex Issues of Cardiovascular Diseases
Russian Federation
Competing Interests: Нет конфликта интересов
Russian Federation
Mamchur Sergei E. - PhD, Head of the Department of Cardiovascular Diseases Diagnosis, Head of the Laboratory of Cardiac Arrhythmia and Pacing.
6, Sosnoviy Blvd., Kemerovo, 650002
Competing Interests: Нет конфликта интересов
E. A. Khomenko
Federal State Budgetary Institution Research Institute for Complex Issues of Cardiovascular Diseases; State Budgetary Healthcare Institution of the Kemerovo Region Kemerovo Regional Clinical Cardiology Dispensary n.a. Academician L.S. Barbarash
Russian Federation
Competing Interests: Нет конфликта интересов
Russian Federation
Khomenko Yegor A. - PhD, researcher at the Laboratory of Cardiac Arrhythmia and Pacing, RICCD; interventional cardiologist at the SBHIKRCCD n.a. Academician L.S. Barbarash.
6, Sosnoviy Blvd., Kemerovo, 650002
Competing Interests: Нет конфликта интересов
O. M. Polikutina
Federal State Budgetary Institution Research Institute for Complex Issues of Cardiovascular Diseases
Russian Federation
Competing Interests: Нет конфликта интересов
Russian Federation
Polikutina Olga M. - MD, PhD, Head of the Laboratory of Ultrasound and Electrophysiological Methods.
6, Sosnoviy Blvd., Kemerovo, 650002
Competing Interests: Нет конфликта интересов
References
1. Hart RG, Pearce LA, Aguilar MI. Meta-analysis; antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146: 857-867
2. Hindricks G., Piorkowski C., Tanner H., Kobza R., GerdsLi J.H., Carbucicchio C., Kottkamp H. Perception of atrial fibrillation before and after radiofrequency catheter ablation: relevance of asymptomatic arrhythmia recurrence. Circulation. 2005; 112(3): 307-313
3. Verma A., Champagne J., Sapp J., Essebag V., Novak P., Skanes A., Morillo C.A., Khaykin Y., Birnie D. Discerning the incidence of symptomatic and asymptomatic episodes of atrial fibrillation before and after catheter ablation (DISCERN AF): a prospective, multicenter study. JAMA Intern Med. 2013; Vol. 173(2): 149-156. doi: 10.1001/jamainternmed.2013.1561.
4. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Available at: http://www.heartrhythmjournal.com/article/S1547-5271(17)30590-8/fulltext. (accessed 06.12.2018).
5. Passman R., Leong-Sit P., Andrei A.C., Huskin A., Tomson T.T., Bernstein R. et al. Targeted anticoagulation for atrial fibrillation guided by continuous rhythm assessment with an insertable cardiac monitor: The Rhythm Evaluation for Anticoagulation With Continuous Monitoring (REACT.COM) pilot study. J Cardiovasc Electrophysiol. 2016; 27: 264-270. doi: 10.1111/jce.12864
6. Zuern C.S., Killias A., Berlitz P., Seizer P., Gramlich M., Muller K. et. al. Anticoagulation after catheter ablation of atrial fibrillation guided by implantable cardiac monitors. PACE. 2015; 38: 688-693. doi: 10.1111/pace.12625.
7. Lin H.J., Wolf P.A., Kelly-Hayes M., Beiser A.S., Kase C.S., Benjamin E.J., D'Agostino R.B. Stroke severity in atrial fibrillation. The Framingham Study. Stroke. 1996;27(10):1760-1764
8. Feng W., Hendry R.M., Adams R.J. Risk of recurrent stroke, myocardial infarction, or death in hospitalized stroke patients. Neurology. 2010; 74(7): 588-593. doi: 10.1212/WNL.0b013e3181cff776.
9. Ziegler P.D., Koehler J.L., Mehra R. Comparison of continuous versus intermittent monitoring of atrial arrhythmias. Heart Rhythm. 2006; 3(12): 1445-1452.
10. Evtushenko V.V., Polikutina O.M., Mamchur S.E., Chichkova T.Y., Romanova M.P. Methods for long-term ecg monitoring in the outpatient settings: a review. Complex Issues of Cardiovascular Diseases. 2017;6(4):133-137. doi: https://doi.org/10.17802/2306-1278-2017-6-4-133-137 (In Russian)
11. Ziegler P.D., Glotzer T.V., Daoud E.G., Wyse D.G., Singer D.E., Ezekowitz M.D., Koehler JL, Hilker CE.Incidence of newly detected atrial arrhythmias via implantable devices in patients with a history of thromboembolic events. Stroke; 2010; 41(2): 256-60. doi: 10.1161/STROKEAHA.109.571455.
12. Healey J.S., Connolly S.J., Gold M.R., Israel C.W., VanGelder I.C., Capucci A. et al. ASSERT Investigators. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med; 2012; 366 (2):120-129. doi: 10.1056/NEJMoa1105575.
13. Perera K.S., Sharma M., Connolly S.J., Wang J., Gold M.R., Hohnloser S.H. et al. Stroke type and severity in patients with subclinical atrial fibrillation: An analysis from the Asymptomatic Atrial Fibrillation and Stroke Evaluation in Pacemaker Patients and the Atrial Fibrillation Reduction Atrial Pacing Trial (ASSERT). Am Heart J. 2018 Jul;201:160-163. doi: 10.1016/j.ahj.2018.03.027.
14. Van Gelder I.C., Healey J.S., Crijns H.J.G.M., Wang J., Hohnloser S.H., Gold M.R. et al. Duration of devicedetected subclinical atrial fibrillation and occurrence of stroke in ASSERT. Eur Heart J; (2017); 38 (17): 1339-1344. doi: 10.1093/eurheartj/ehx042.
15. Glotzer T.V., Daoud E.G., Wyse D.G., Singer D.E., Ezekowitz M.D., Hilker C., Miller C., Qi. D., Ziegler P.D. The relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics and stroke risk: the TRENDS study. Circ Arrhythm Electrophysiol; 2009;2: 474-480. doi: 10.1161/CIRCEP.109.849638.
16. Sanna T., Diener H.C., Passman R.S., Di Lazzaro V., Bernstein R.A., Morillo C.A. et al. Cryptogenic Stroke and Underlying Atrial Fibrillation. N Engl J Med 2014; 370:24782486. DOI: 10.1056/NEJMoa1313600
17. Sacco R.L., Prabhakaran S., Thompson J.L., Murphy A., Sciacca R.R., Levin B., Mohr J.P. Comparison of warfarin versus aspirin for the prevention of recurrent stroke or death: subgroup analyses from the Warfarin-Aspirin Recurrent Stroke Study. Cerebrovasc Dis; 2006;22(1):4-12. DOI: 10.1159/000092331
18. Hart R.G., Sharma M., Mundl H., Kasner S.E., Bangdiwala S.I., Berkowitz S.D. et al. Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source. N Engl J Med; 2018; 7;378(23):2191-2201. DOI: 10.1056/NEJMoa1802686
19. Diener H.C., Easton J.D., Granger C.B., Cronin L., Duffy C., Cotton D., Brueckmann M., Sacco R.L. Design of Randomized, double-blind, Evaluation in secondary Stroke Prevention comparing the EfficaCy and safety of the oral Thrombin inhibitor dabigatran etexilate vs. acetylsalicylic acid in patients with Embolic Stroke of Undetermined Source (RE-SPECT ESUS). Int J Stroke; 2015;10(8):1309-12. doi: 10.1111/ijs.12630.
20. Apixaban for Treatment of Embolic Stroke of Undetermined Source (ATTICUS). Available at: https://clinicaltrials.gov/ct2/show/NCT02427126?term=ATTICUS&r ank=1. (accessed 04.11.2018)
21. Verma N., Ziegler P.D., Liu S., Passman R.S. Incidence of atrial fibrillation among patients with an embolic stroke of undetermined source: Insights from insertable cardiac monitors. Int J Stroke. 2018 Sep 10:1747493018798554. doi: 10.1177/1747493018798554
22. Kamel H., Okin P.M., Elkind M.S., Iadecola C. Atrial Fibrillation and Mechanisms of Stroke. Time for a New Model. Stroke. 2016 Mar;47(3):895-900. doi: 10.1161/STROKEAHA.115.012004.
23. Hindricks G., Pokushalov E., Urban L., Taborsky M., Kuck K.H., Lebedev D. Performance of a New Leadless Implantable Cardiac Monitor in Detecting and Quantifying Atrial Fibrillation Results of the XPECT Trial. Circ Arrhythm Electrophysiol. 2010 Apr;3(2):141-7. doi: 10.1161/CIRCEP.109.877852.
24. Implantiruemyj monitor: rukovodstvo vracha. Medtronic. Available at: http://manuals.medtronic.com/content/dam/emanuals/ crdm/CONTRIB_222015.pdf (accessed 04.11.2018)
25. Lee R., Mittal S.. Utility and limitations of long-term monitoring of atrial fibrillation using an implantable loop recorder. Heart Rhythm; 15(2): 287-295. doi: 10.1016/j.hrthm.2017.09.009.
26. Podd S.J., Sugihara C., Furniss S.S., Sulke N. Are implantable cardiac monitors the “gold standard” for atrial fibrillation detection? A prospective randomized trial comparing atrial fibrillation monitoring using implantable cardiac monitors and DDDRP permanent pacemakers in post fibrillation ablation patients. Europace; 2016; 18: 1000-1005. doi: 10.1093/europace/euv367.
Review
For citations:
Chichkova T.Y., Mamchur I.E., Khomenko E.A., Polikutina O.M. Long-term ECG monitoring. Significance for primary and secondary prevention of thromboembolic events in atrial fibrillation. Complex Issues of Cardiovascular Diseases. 2018;7(4S):94-100. (In Russ.) https://doi.org/10.17802/2306-1278-2018-7-4S-94-100
Views:
749
